The FDA has approved Guardant Health’s Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim’s Hernexeos (zongertinib), using a blood draw to identify adults with unresectable or metastatic non-squamous NSCLC harboring HER2 (ERBB2) tyrosine kinase domain activating mutations who may benefit from treatment. The move pairs a liquid biopsy with a newly cleared front-line HER2-mutant lung cancer therapy, building on Beamion LUNG-1 data in which zongertinib delivered a 66.7% objective response rate in pre-treated advanced NSCLC.

Why It Matters To Oncology

• Blood-based companion diagnostics can speed treatment matching when tissue is limited, delayed or insufficient for molecular profiling.

• For clinicians, the approval expands noninvasive testing options in a genomically defined NSCLC subset where identifying HER2 mutations is essential for therapy selection.

• Guardant360 CDx now has 27 companion diagnostic indications globally, including prior FDA nods tied to NSCLC agents such as Tagrisso, Rybrevant, Lumakras and Enhertu.

• A large Nature Medicine study previously found patients with advanced cancer who received targeted therapy selected using Guardant360 CDx results survived twice as long as those who did not.

The Financials

• Neither company disclosed financial terms tied to this specific approval.

• Commercially, the decision strengthens Guardant’s position in liquid biopsy and adds another marketed companion diagnostic use case for Boehringer’s lung cancer franchise.

• For drug developers, the approval reinforces the value of parallel diagnostic-drug strategies in biomarker-defined oncology markets.

What They're Saying

• Guardant co-CEO Helmy Eltoukhy said the approval “highlights the growing impact of liquid biopsy across advanced cancer care and underscores the utility of Guardant360 CDx to ensuring more patients can be matched to the right therapy at the right time.”

• The broader message: liquid biopsy is moving beyond profiling into frontline treatment-enabling infrastructure for precision oncology.

What's Next

• Clinicians will be watching how quickly blood-based HER2 mutation testing is adopted in first-line NSCLC workflows alongside or ahead of tissue testing.

• Drug discovery teams may view the clearance as another proof point that companion diagnostics can expand access to biomarker-selected therapies and support uptake after drug approval.

• Expect continued focus on whether liquid biopsy-guided treatment selection improves real-world time to therapy, testing rates and outcomes in HER2-mutant malignant neoplasm of the lung.